Do Not Add Augmentin to Keflex for Hand Cellulitis
You should not add Augmentin (amoxicillin-clavulanate) to Keflex (cephalexin) for hand cellulitis—this represents unnecessary dual beta-lactam therapy with overlapping coverage and no demonstrated benefit.
Why This Combination Is Not Recommended
Overlapping Spectrum of Activity
Both Keflex and Augmentin are beta-lactam antibiotics that cover the same pathogens responsible for typical cellulitis:
- Both cover β-hemolytic streptococci (the primary cause of nonpurulent cellulitis)
- Both cover methicillin-susceptible Staphylococcus aureus (MSSA)
- Using both simultaneously provides no additional pathogen coverage 1
Guideline-Based Approach to Hand Cellulitis
The IDSA guidelines clearly stratify cellulitis treatment based on clinical presentation 2, 1:
For nonpurulent cellulitis (no purulent drainage, no abscess):
- First-line: Beta-lactam monotherapy targeting β-hemolytic streptococci
- Keflex (cephalexin) alone is appropriate 1
- Duration: 5-10 days based on clinical response 1
Hand location is specifically mentioned as requiring antibiotic therapy (not just incision and drainage alone) due to difficulty draining this anatomical site 1.
When to Modify Treatment
Add MRSA coverage (not another beta-lactam) if 1, 3:
- No clinical response to beta-lactam therapy after 48-72 hours
- Purulent drainage develops
- Systemic toxicity present
- Penetrating trauma or injection drug use history
- Known MRSA colonization
MRSA coverage options to ADD (not Augmentin):
- TMP-SMX (trimethoprim-sulfamethoxazole) PLUS continue beta-lactam 1
- Doxycycline PLUS continue beta-lactam 1
- Switch to clindamycin monotherapy 1
Evidence Against Dual Beta-Lactam Therapy
A double-blind study demonstrated that combination therapy with TMP-SMX plus cephalexin was no more efficacious than cephalexin alone for pure cellulitis 3. This reinforces that adding additional coverage when beta-lactam monotherapy is appropriate provides no benefit.
Recent evidence confirms that beta-lactam monotherapy (cefazolin or oxacillin) was successful in 96% of cellulitis patients, indicating MRSA is an uncommon cause of typical cellulitis and dual therapy is unnecessary 3.
Practical Management Algorithm
If patient is currently on Keflex:
Assess clinical presentation:
- Nonpurulent (no pus, no abscess) → Continue Keflex alone
- Purulent features → Add MRSA coverage (TMP-SMX or doxycycline)
Evaluate response at 48-72 hours:
Consider switching (not adding) to Augmentin only if:
- Concern for oral anaerobes (human/animal bite)
- This is a switch, not combination therapy
Common Pitfall to Avoid
Do not reflexively add broad-spectrum coverage or combine beta-lactams simply because the infection involves the hand. Hand cellulitis follows the same treatment principles as cellulitis elsewhere—monotherapy with appropriate beta-lactam is sufficient for nonpurulent presentations 1, 3.
The 2021 American College of Physicians guidelines recommend 5-6 days of antibiotics active against streptococci for nonpurulent cellulitis, emphasizing shorter courses with close follow-up rather than broader or combination therapy 4.
Bottom line: Continue Keflex alone for 5-10 days. Only add MRSA-specific coverage (not Augmentin) if clinical features suggest MRSA or if there's treatment failure.